Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib added to azacitidine + venetoclax for newly diagnosed NPM1-mutated or KMT2A-rearranged AML in adults ineligible for intensive chemotherapy
NL-OMON58913Phase 3Recruiting
- Sponsor
- HOVON
- Start
- Mar 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in acute myeloid leukemia (AML) comparing Revumenib + azacitidine + venetoclax with Azacitidine + venetoclax (2 arms). Primary endpoints: Overall survival in NPM1-mutated AML and Complete remission rate in NPM1-mutated AML. Started Mar 2025; status: recruiting.
02
Drugs
revumenibvenetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON58913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58913.